Shares of Sunshine Biopharma Inc. (NASDAQ:SBFM) tumbled 17.2% in premarket trading Wednesday after the company disclosed a filing to sell up to $6 million worth of securities in a dilutive offering.
Under the proposed transaction, the company has registered up to 5,825,242 common units on a best-efforts basis. Each common unit would consist of one share of Sunshine Biopharma common stock and two Series C Warrants. The Series C Warrants are structured with an initial exercise price of $1.03 per share and would be exercisable for a five-year term.
Sunshine Biopharma also intends to make available pre-funded units to certain purchasers whose acquisition would otherwise result in ownership in excess of 4.99% or 9.99% of the outstanding common shares. Each pre-funded unit will include one pre-funded warrant to purchase a single share of common stock and two Series C Warrants. The stated purchase price for each pre-funded unit is $1.02999, and the pre-funded warrant will carry an exercise price of $0.00001 per share.
The filing is based on an assumed public offering price of $1.03 per common unit, a figure that the company says matched the last reported sale price of its common stock on May 11, 2026. The final offering price, however, will be negotiated among Sunshine Biopharma, placement agent Aegis Capital Corp., and prospective investors. The company notes that the actual price could be set at a discount to the then-current market price.
There is no stated minimum for the offering to close, which means aggregate proceeds could be materially lower than the $6 million cap. The company has said it expects the offering to terminate no later than June 30, 2026.
Aegis Capital Corp. is acting as the exclusive placement agent on a best-efforts basis. Compensation for its services will include placement agent fees plus a non-accountable expense allowance equal to 2.0% of aggregate gross proceeds.
Sunshine Biopharma has clarified that the common units and pre-funded units will carry no separate rights, will not be certificated, and the company does not intend to list the units or the attached warrants on any securities exchange.
The filing and its terms highlight several capital-raising mechanics that can affect shareholder value in the near term, including the issuance of warrants with multi-year exercisability, pre-funded instruments designed to manage ownership caps, and a lack of minimum funding that leaves final proceeds uncertain.